ET Pharma

Announcing The Economic Times RE Pharma Summit 2025! Join us on 8th February 2025 at the Courtyard by Marriott, Mumbai, for a transformative event as we explore the shift from cost-based to value-based models in the pharmaceutical industry. Featuring key thought leaders, insightful discussions, and an awards ceremony, this is an opportunity to stay ahead of the curve in pharma innovation. Express your interest now: https://lnkd.in/gpWVhTZ6 #ETREPharmaSummit #PharmaInnovation #ValueBasedCare #HealthcareLeadership #PharmaAwards

Join us at The Economic Times RE Pharma Summit, where pivotal discussions will shape the future of India's pharmaceutical industry. We’ll explore the shift from cost-based to value-based models, delve into understanding healthcare practitioners, and reimagine the Med-Rep approach. Other key topics include capitalizing on India's opportunities in access and pricing, and the ongoing debate between generic and branded prescriptions. Don’t miss this transformative event! Register Now: bit.ly/4gHco2N #ETRePharmaSummit #PharmaInnovation #HealthcareLeadership #EconomicTimes #Summit2025 #HealthcareTransformation #PharmaIndustry #MedRepReform

Small Molecules Era Fades: Experts Urge Focus on Biologics and Large Molecules At the ETPharma’s Future-Ready Supply Chain Summit, experts highlighted that for India to capitalise on the China +1 shift, it must focus on backend products like APIs and expand into large molecules and biologics. Regarding the Biosecure Act, experts see long-term opportunities in pre-clinical drugs, but late-stage (Phase 2, 3) products are unlikely to come to India. #Pharma_SupplyChain I #China I #US I #BiosecureAct I #API I #Biologics I #Large_Molecules I #India I Annasswamy Vaidheesh I Yugal Sikri I Sreenivas Rao Nandigam I Abhay Kumar Srivastava I Arunabha Raychaudhuri I Chandrachur Datta I Prathiba Raju I Suven Pharmaceuticals I SUN PHARMA I RPG Life Sciences Ltd. I MANKIND PHARMA LTD I Vector Consulting Group I PI Industries Ltd Read more: https://lnkd.in/gypR-ZbA

US FDA approves Ionis Pharma's genetic disorder drug The drug, chemically known as olezarsen and branded as Tryngolza, is also the first approved treatment for familial chylomicronemia syndrome (FCS), a disorder that prevents the body from breaking down fats and is characterized by extremely high levels of triglycerides. #FDAApproval | #RareDiseases | #Triglycerides | #GeneticDisorders | #PharmaInnovation | #LipoproteinLipase | #DrugApproval | #PatientCare Read more: https://lnkd.in/e2eTJyNh

US FDA declines to approve Zealand Pharma's bowel disease drug The health regulator concluded in its so-called complete response letter that Zealand's application did not provide enough evidence to prove the effectiveness and safety of the proposed dose of the drug, glepaglutide, the company said. #BowelDisease | #DrugApproval | #ShortBowelSyndrome | #ClinicalTrials | #PharmaIndustry | #DrugSafety | #RareDiseases | #BiotechNews Read more: https://lnkd.in/e72BjzmX

Merck's HIV treatment meets main goal in two late-stage studies The U.S. drugmaker is seeking new growth drivers to offset a potential hit from its blockbuster cancer immunotherapy Keytruda losing patent protection toward the end of the decade. #HIVTreatment | #HIVResearch | #AntiretroviralTherapy | #HIVSuppression | #ClinicalTrials | #PharmaceuticalInnovation | #HIVAwareness Read more: https://lnkd.in/eV_FzyBr

In weight loss battle, Novo and Lilly face growing offensive from licenced copies Ozempic's patented semaglutide ingredient is also used in Novo's wildly popular obesity treatment Wegovy and diabetes tablets Rybelsus, while Lilly's tirzepatide is used in Mounjaro and Zepbound. This year, at least seven new products containing semaglutide have been approved for sale in Laos and Russia, according to public lists of licenced drugs, comments from a regulatory official, details of two approved medicines in Paraguay obtained via a freedom of information request, and information on the websites of two drug manufacturers. #NovoNordisk | #WeightLossDrugs | #DiabetesTreatment | #PharmaIndustry | #DrugApproval | #Semaglutide Read more: https://lnkd.in/esHEUQMS

Steps to rein in pharmacy benefit managers in US bill "manageable" for firms The stopgap measure aimed at averting a partial government shutdown includes a healthcare package that prohibits these companies from deriving remuneration based on a drug's Medicare list price. #PharmacyBenefitManagers | #DrugPricing | #HealthcareReform | #MedicareChanges | #PharmaIndustry Read more: https://lnkd.in/eYyr2VwA

US accuses CVS of filling, billing government for illegal opioid prescriptions The newly unsealed complaint in Providence, Rhode Island federal court alleges that, from October 2013 to the present, CVS violated the federal Controlled Substances Act by filling prescriptions for dangerous quantities of opioids and dangerous combinations of drugs. #PharmacyAccountability | #ControlledSubstancesAct | #OpioidEpidemic | #PublicHealth | #HealthcareEthics Read more: https://lnkd.in/eqVwDDeZ

J&J drug helps delay multiple myeloma in high-risk patients Darzalex, a monoclonal antibody that targets a protein found on the surface of myeloma cells known as CD38, significantly reduced patients' risk of developing the blood cancer and improved their survival in an international late-stage trial.  #CancerResearch | #MonoclonalAntibody | #CancerTreatment | #Hematology | #MedicalBreakthrough Read more: https://lnkd.in/eNMgTBPU